PMN

ProMIS Neurosciences, Inc.
CAPPED RATING

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciences, Inc. (PMN) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
C
Factor Score 2.5 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.5
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -77.6%
Price Return 12M -67.9%
Catalyst Signal 0.00
Market Cap $29.5M
TTM Revenue N/A
Price / Sales N/A
ROE -172.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) D- (1.1) C (2.5) D+ (1.5) C+ (2.6) C- (2.0)
2026-11-07 C+ (2.5) C- (2.0) C (2.5) D+ (1.7) C+ (2.7) C (2.3)
2026-10-31 C+ (2.5) C- (2.0) C+ (2.6) D+ (1.6) C+ (2.7) C (2.3)
2026-10-24 C+ (2.5) C- (2.0) C+ (2.5) C (2.3) C+ (2.6) C (2.4)
2026-10-17 C+ (2.5) C- (2.0) C+ (2.5) C (2.3) C+ (2.6) C (2.4)
Page 1 of 3